ArticleFrontiers in pediatrics2025
Lung ultrasound imaging can effectively monitor and guide treatment with pulmonary surfactant for preterm infants of pulmonary consolidation: a prospective observational cohort study.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lung ultrasound-guided positioning strategy for the prevention of ventilator-associated pneumonia in neonates.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A radiation-free method for dynamic evaluation of infant lung function is lung ultrasound (LUS). Objective: To assess if LUS-guided surfactant therapy, which is based on direct observation of pulmonary consolidation, is an effective way to guide treatment timing and dosage in preterm infants (less than 34 weeks of gestation). Methods: This prospective observational cohort study was conducted at Dehong Hospital affiliated to Kunming Medical University, in various clinical settings, including newborn wards, neonatal intensive care units (NICUs), obstetric operating rooms and delivery rooms. Within an hour of delivery, all preterm newborns received their first LUS. The frequency of monitoring was adjusted for those without consolidation at various intervals; if consolidation was detected, PS[Poractant alfa (Curosur®; Chiesi Farmaceutici S.p.A., Italy)] 200 mg/kg was administered immediately. A repeating dose of 100 mg/kg was administered if consolidation did not go away after 12 h. Following each PS treatment, LUS assessments were conducted every four hours, and monitoring was progressively decreased once consolidation was resolved. PS was not administered to TTN preterm newborns without consolidation. The frequency of PS administration, the prevalence of pulmonary consolidation, and the number of infants who had complete lung re-expansion were also noted. Results: With each PS dose, the rate of complete lung re-expansion among infants with neonatal respiratory distress syndrome (NRDS, Conclusion: In preterm newborns, NRDS and TTN can be effectively managed using LUS-guided PS therapy based on consolidation monitoring. While TTN can be treated with a fixed-dose regimen, NRDS has a dose-response relationship that supports customized dosage. The frequency and timing of surfactant administration in preterm newborns are determined by LUS-detected lung consolidation, which also acts as a decision-making indicator for PS therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.